Long Term Experience With Abatacept in Routine Clinical Practice

Trial Profile

Long Term Experience With Abatacept in Routine Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ACTION
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Jun 2017 Results of treatment patterns and switching of abatacept formulation over two years (n=2350) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Primary endpoint has been met. (Treatment continuation) as per results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results determining patient biologic DMARD use prior to initiation and after discontinuation of ABA overall and by treatment line presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top